- Home
- FVR vs TRVI Comparison
FVR vs TRVI Comparison
Compare FVR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FVR
- TRVI
- Stock Information
- Founded
- FVR 2016
- TRVI 2011
- Country
- FVR United States
- TRVI United States
- Employees
- FVR N/A
- TRVI N/A
- Industry
- FVR
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- FVR
- TRVI Health Care
- Exchange
- FVR NYSE
- TRVI Nasdaq
- Market Cap
- FVR 288.4M
- TRVI 341.4M
- IPO Year
- FVR 2024
- TRVI 2019
- Fundamental
- Price
- FVR $17.04
- TRVI $3.76
- Analyst Decision
- FVR Strong Buy
- TRVI Strong Buy
- Analyst Count
- FVR 5
- TRVI 8
- Target Price
- FVR $21.80
- TRVI $9.31
- AVG Volume (30 Days)
- FVR 386.3K
- TRVI 659.4K
- Earning Date
- FVR 11-13-2024
- TRVI 11-06-2024
- Dividend Yield
- FVR 1.26%
- TRVI N/A
- EPS Growth
- FVR N/A
- TRVI N/A
- EPS
- FVR N/A
- TRVI N/A
- Revenue
- FVR $58,655,152.00
- TRVI N/A
- Revenue This Year
- FVR N/A
- TRVI N/A
- Revenue Next Year
- FVR $18.00
- TRVI N/A
- P/E Ratio
- FVR N/A
- TRVI N/A
- Revenue Growth
- FVR N/A
- TRVI N/A
- 52 Week Low
- FVR $15.30
- TRVI $1.27
- 52 Week High
- FVR $19.76
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- FVR N/A
- TRVI 48.03
- Support Level
- FVR N/A
- TRVI $3.63
- Resistance Level
- FVR N/A
- TRVI $4.06
- Average True Range (ATR)
- FVR 0.00
- TRVI 0.30
- MACD
- FVR 0.00
- TRVI -0.09
- Stochastic Oscillator
- FVR 0.00
- TRVI 12.21
About FVR FRONTVIEW REIT INC
FrontView REIT Inc is an internally managed net-lease REIT that is experienced in acquiring, owning, and managing out parcel properties that are net-leased to a diversified group of tenants. Its tenants include service-oriented businesses, such as restaurants, cellular stores, financial institutions, automotive stores and dealers, medical and dental providers, pharmacies, convenience and gas stores, car washes, home improvement stores, grocery stores, professional services as well as general retail tenants.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.